Smart Mesoporous Silica Nanoparticles in Cancer: Diagnosis, Treatment, Immunogenicity, and Clinical Translation

Abstract In cancer research and personalized medicine, mesoporous silica nanoparticles (MSNs) have emerged as a significant breakthrough in both cancer treatment and diagnosis. MSNs offer targeted drug delivery, enhancing therapeutic effectiveness while minimizing adverse effects on healthy cells. Due to their unique characteristics, MSNs provide targeted drug delivery, maximizing therapeutic effectiveness with minimal adverse effects on healthy cells. The review thoroughly investigates the role of MSNs as potent drug carriers, noted for their high drug‐loading capacity and controlled release, which significantly improves drug permeability and retention. Additionally, it discusses surface modification techniques that enable MSNs to target cancer cells precisely. The manuscript provides comprehensive insights into various MSN applications, including their role in cancer diagnosis, the design of advanced biosensors, and the development of both conventional and stimuli‐responsive drug delivery platforms. Special focus is given to stimuli‐triggered MSN systems, responsive to internal stimuli (e.g., pH, redox, enzyme) and external stimuli (e.g., temperature, magnetic field, light, ultrasound), highlighting the cutting‐edge progress in MSN technology. Additionally, the review delves into the immunogenicity and biosafety aspects of MSNs, underscoring their potential for clinical translation. Besides summarizing the current state of MSN research in oncology, this review also illuminates the path for future advancements and clinical applications.